Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study (vol 41, pg 3523, 2023)

被引：0
|
作者：
Cartron
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 25期
关键词：
D O I：
10.1200/JCO.23.01377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4187 / 4187
页数：1
相关论文
共 50 条
  • [31] Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany)
    Rummel, Mathias J.
    Niederle, Norbert
    Maschmeyer, Georg
    Banat, Andre
    von Gruenhagen, Ulrich
    Losem, Christoph
    Heil, Gerhard
    Welslau, Manfred
    Balser, Christina
    Kaiser, Ulrich
    Ballo, Harald
    Weidmann, Eckhart
    Duerk, Heinz A.
    Kofahl-Krause, Dorothea
    Roller, Fritz
    Barth, Juergen
    Hoelzer, Dieter
    Hinke, Axel
    Brugger, Wolfram
    BLOOD, 2009, 114 (22) : 168 - 169
  • [32] Results of the Interim Analysis of the "HUSOM" Trial: Hungarian Study of Maintenance After Rituximab Pretreatment, A Multicentre, Phase III, Open-Label Study Evaluating the Benefit of a Long-Term MabThera (rituximab) Maintenance Therapy in Patients with Advance Follicular Lymphoma After Induction of Response (CR(u) or PR) with a MabThera (rituximab)-Containing First Line Regimen
    Schneider, Tamas J.
    Rosta, Andras
    Losonczy, Hajna
    Radvanyi, Gaspar
    Ujj, Gyorgy
    Illes, Arpad
    Jakucs, Janos
    Borbenyi, Zita
    BLOOD, 2011, 118 (21) : 1168 - 1168
  • [33] Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma -: Results of a prospective Randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Hiddemann, W
    Dreyling, MH
    Forstpointner, R
    Kneba, M
    Woermann, B
    Lengfelder, E
    Schmits, R
    Reiser, M
    Metzner, B
    Schmitz, N
    Truemper, L
    Eimermacher, H
    Parwaresch, R
    BLOOD, 2003, 102 (11) : 104A - 104A
  • [34] FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study (vol 41, pg 4143, 2023)
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30)
  • [35] Four versus two years of Rituximab maintenance (R-maintenance) following Bendamustine plus Rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study)
    Rummel, M.
    Buske, C.
    Hertenstein, B.
    Lerchenmueller, C. A.
    Koenigsmann, M.
    Lange, E.
    Reeb, M.
    Kaiser, U.
    Balser, C.
    Behringer, D.
    Duerig, J.
    Gaska, T.
    Maschmeyer, G.
    Schliesser, G.
    Burchardt, A.
    Barth, J.
    Kauff, F.
    Hinke, A.
    Greil, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 251 - 251
  • [36] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial (vol 11, pg, 82, 2011)
    Roberts, Nicholas
    CLINICAL BREAST CANCER, 2011, 11 (04) : 273 - 273
  • [37] Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)
    Rummel, Mathias J.
    Buske, Christian
    Hertenstein, Bernd
    Lerchenmueller, Christian
    Koenigsmann, Michael
    Lange, Elisabeth
    Reeb, Manfred
    Kaiser, Ulrich
    Balser, Christina
    Behringer, Dirk
    Durig, Jan
    Gaska, Tobias
    Maschmeyer, Georg
    Schliesser, Georg
    Burchardt, Alexander Christoph
    Barth, Juergen
    Kauff, Frank
    Hinke, Axel
    Greil, Richard
    BLOOD, 2017, 130
  • [38] Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: Stage 1 results of the phase III SABRINA study
    Davies, A. J.
    Merli, F.
    Mihaljevic, B.
    Siritanaratkul, N.
    Solal-Celigny, P.
    Boehnke, A.
    Berge, C.
    McIntyre, C.
    Barrett, M.
    MacDonald, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 7 - 8
  • [39] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer (vol 26, pg 5544, 2008)
    Leo, Di
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1923 - 1923
  • [40] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans-Joachim Lück
    Andreas Du Bois
    Sibylle Loibl
    Iris Schrader
    Jens Huober
    Volker Heilmann
    Matthias Beckmann
    Ann Stähler
    Christian Jackisch
    Michael Hubalek
    Barbara Richter
    Elmar Stickeler
    Holger Eidtmann
    Christoph Thomssen
    Michael Untch
    Kerstin Wollschläger
    Tibor Schuster
    Gunter von Minckwitz
    Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
12345